EML4-ALK fusion as a resistance mechanism to osimertinib and its successful management with osimertinib and alectinib: case report and review of the literature
Conclusion Osimertinib has an important place in the management of EGFR-mutant NSCLC.
It can be used up front (FLAURA trial) or as a part of sequential therapy (AURA trial). 7, 24
However, disease inevitably progresses with osimertinib, and patients are then subjected to
chemotherapy. In this era of precision medicine, rebiopsy at progression and understanding
resistance mechanisms through broad-based multiplex NGS methods may pave the way for
further patient management. The use of combination TKI therapy
It can be used up front (FLAURA trial) or as a part of sequential therapy (AURA trial). 7, 24
However, disease inevitably progresses with osimertinib, and patients are then subjected to
chemotherapy. In this era of precision medicine, rebiopsy at progression and understanding
resistance mechanisms through broad-based multiplex NGS methods may pave the way for
further patient management. The use of combination TKI therapy
Conclusion
Osimertinib has an important place in the management of EGFR-mutant NSCLC. It can be used up front (FLAURA trial) or as a part of sequential therapy (AURA trial). 7, 24 However, disease inevitably progresses with osimertinib, and patients are then subjected to chemotherapy. In this era of precision medicine, rebiopsy at progression and understanding resistance mechanisms through broad-based multiplex NGS methods may pave the way for further patient management. The use of combination TKI therapy
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果